A recent study confirms an association between vessel co-option and resistance to bevacizumab, an anti-vascular endothelial growth factor-A (VEGFA) antibody, in patients with liver metastases. The authors suggest a combined therapeutic strategy that reduces co-option in mice.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Jain, R.K. Cancer Cell 26, 605–622 (2014).
Bergers, G. & Hanahan, D. Nat. Rev. Cancer 8, 592–603 (2008).
Frentzas, S. et al. Nat. Med. 22, 1294–1302 (2016).
Vermeulen, P.B. et al. J. Pathol. 195, 336–342 (2001).
Donnem, T. et al. Cancer Med. 2, 427–436 (2013).
Jeong, H.S. et al. J. Natl. Cancer Inst. 107, djv155 (2015).
Stessels, F. et al. Br. J. Cancer 90, 1429–1436 (2004).
Carmeliet, P. & Jain, R.K. Nature 473, 298–307 (2011).
Rahbari, N.N. et al. Sci. Transl. Med. 8, 360ra135 (2016).
Gilkes, D.M., Semenza, G.L. & Wirtz, D. Nat. Rev. Cancer 14, 430–439 (2014).
K.E.E. has no conflicts of interest. E.K.J. has received consultant fees from Enlight, Ophthotech, SPARC and SynDevRx, owns equity in Enlight, Ophthotech, SynDevRx and XTuit, and serves on the Board of Directors of XTuit and the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. No funding or reagents from these companies were used in this study.
Rights and permissions
About this article
Cite this article
Emblem, K., Jain, R. Improving treatment of liver metastases by targeting nonangiogenic mechanisms. Nat Med 22, 1209–1210 (2016). https://doi.org/10.1038/nm.4228